Core Viewpoint - Hanyu Pharmaceutical is experiencing significant growth, with a projected net profit increase of 1470.82% to 1663.89% for the first half of 2025 compared to the same period last year [1][2] Group 1: Financial Performance - The company expects to achieve a net profit of between 142 million to 162 million yuan for the first half of 2025 [1] - This represents a substantial increase compared to the previous year's performance [1] Group 2: International Business Expansion - Hanyu Pharmaceutical's international business has expanded to core global markets, with APIs sold to over 20 countries and formulations licensed in more than 90 countries [1] - The company is accelerating its internationalization process, which is expected to enhance growth potential [2] Group 3: Innovation in Drug Development - The company focuses on innovative drug development, particularly in the field of peptides and small nucleic acids, with a rich pipeline of future products [2] - The HY3003 project, a GLP-1R/GIPR/GCGR receptor agonist, has completed preclinical candidate screening and is advancing to the pilot scale of API production [1] - The project employs a multi-formulation development strategy, including long-acting monthly injections to improve patient compliance [1] Group 4: Future Product Pipeline - Hanyu Pharmaceutical plans to launch no fewer than 20 formulations globally, including original innovative drugs and micro-innovative drugs [2] - The pipeline includes drugs for treating conditions such as high cholesterol, hypertension, and diabetes, featuring products like Inclisiran and Zilebesiran [2]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen stock markets have announced significant updates, including changes in financing, business performance, and strategic decisions, which may impact investor sentiment and market dynamics [1]. Financing and Restructuring - Guanhao Biological has withdrawn its application for refinancing, leading to the termination of the review process by the Shenzhen Stock Exchange [3]. - Jinhongshun has terminated its major asset restructuring plan due to a lack of consensus among parties involved [6]. - Yuyuan Co. plans to issue bonds not exceeding 40 billion yuan to adjust its debt structure and replenish working capital [23]. Business Performance and Uncertainties - Aored has highlighted significant uncertainties in its computing power leasing services due to heavy asset investment and potential market fluctuations [4]. - Guoyao Modern intends to publicly transfer 51% of its subsidiary Guoyao Hason's shares, as the subsidiary has been underperforming with continuous losses since 2021 [5]. - Chengbang Co. reported that its subsidiary, Xinchun Electronics, has a small business scale and faces intense competition in the semiconductor storage industry, with projected revenues of 111 million yuan and a net profit of 933,800 yuan for 2024 [9]. Stock Market Activity - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock trading resuming on July 1 [7]. - Changcheng Military Industry reported significant stock price volatility, with a cumulative increase of over 100% in the last 10 trading days, indicating potential irrational market behavior [8]. Earnings Forecasts - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, recovering from a loss in the previous year, driven by international business growth [12]. - Taotao Vehicle anticipates a net profit increase of 70.34% to 97.81% for the same period, reflecting strong sales performance [13]. - Weichai Heavy Machinery projects a net profit increase of 40% to 60%, benefiting from industry policy support and demand growth [15]. Major Contracts and Projects - China Railway has won contracts for overseas construction projects totaling approximately 5.343 billion yuan [17]. - Zhonggong International has signed a 175 million yuan engineering consulting service contract [18]. - Hezhan Energy has entered into a 177 million yuan contract for the sale of steel-concrete towers [19].

翰宇药业（300199）公告，预计2025年上半年净利润为1.42亿元–1.62亿元，上年同期为亏损1035.88万 元，同比扭亏为盈。受益于全球市场需求的持续增长、2024年12月23日公司向美国食品药品监督管理局 申报的利拉鲁肽注射液获得批准证书并实现销售、原料药出口持续放量、公司产品的市场竞争力以及严 格的成本控制等多重因素，国际业务的营业利润率较高，进一步推动了公司整体盈利水平的提升。 ...

翰宇药业：上半年预盈1.42亿元至1.62亿元 原料药出口持续放量 智通财经6月30日电，翰宇药业(300199.SZ)公告称，预计2025年上半年归属于上市公司股东的净利润 1.42亿元至1.62亿元，同比扭亏。受益于全球市场需求的持续增长、2024年12月23日公司向美国食品药 品监督管理局申报的利拉鲁肽注射液获得批准证书并实现销售、原料药出口持续放量、公司产品的市场 竞争力以及严格的成本控制等多重因素，国际业务的营业利润率较高，进一步推动了公司整体盈利水平 的提升。 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-034 深圳翰宇药业股份有限公司 2025 年半年度业绩预告 预计净利润为正值且属于下列情形之一： √扭亏为盈 同向上升 同向下降 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：14,200.00 万元–16,200.00 万元 | 亏损：1,035.88 万元 | | | 比上年同期增长：1470.82%-1663.89% | | | 扣除非经常性损益后的净利润 | 盈利：12,200.00 万元–14,200.00 万元 | 亏损：5,972.38 万元 | | | 比上年同期增长：304.27%-337.76% | | 二、与会计师事务所沟通情况 本次业绩预告的相关财务数据未经会计师事务所审计。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日 （二）业绩预告情况 四、其他相关说明 本次业绩预告是公司财务部门初步 ...

Group 1 - Xiansheng Pharmaceutical announced that its insomnia treatment drug Daridorexant (brand name: Kewiko®) has been approved for marketing in China, enhancing patient access and supporting long-term use [1] - HAP Pharmaceutical entered a global strategic collaboration with Otsuka Pharmaceutical to develop a BCMAxCD3 bispecific T-cell engager, receiving an upfront payment of $47 million and potential additional payments up to $623 million based on future milestones [1] - Baotai announced a licensing agreement with Stein for the commercialization rights of BAT2406 (Dupilumab) in Latin America, with total upfront and milestone payments potentially reaching $10 million [1] Group 2 - David Medical received a medical device registration certificate for its electric stretcher, which offers significant advantages over traditional manual devices, improving operational efficiency and reducing the burden on healthcare personnel [2] - Hanyu Pharmaceutical's subsidiary received approval for the listing of its active pharmaceutical ingredient Acetate Degarelix, which is used to treat advanced prostate cancer [3] - China Traditional Chinese Medicine reported that its innovative TCM drug Yushudapin's registration application has been accepted, showing significant efficacy in improving early symptoms of depressive disorders [4]

Market Performance - The cell immunotherapy sector declined by 1.41%, ranking among the top losers in the concept sector as of the market close on June 26 [1] - Notable declines were observed in companies such as Rongchang Biologics, Yuyuan Pharmaceutical, and Huahai Pharmaceutical, while ST Xiangxue, Shutai Shen, and Tailin Biologics saw gains of 4.19%, 1.71%, and 1.42% respectively [1] Capital Flow - The cell immunotherapy sector experienced a net outflow of 796 million yuan, with 43 stocks facing net outflows, and 5 stocks seeing outflows exceeding 50 million yuan [1] - Rongchang Biologics led the outflow with 110 million yuan, followed by Hengrui Medicine, Huahai Pharmaceutical, and Yuyuan Pharmaceutical with outflows of 104 million yuan, 75 million yuan, and 70 million yuan respectively [1] Top Gainers and Losers - The top gainers in the cell immunotherapy sector included ST Xiangxue, Shutai Shen, and Tailin Biologics, while the largest losers were Rongchang Biologics, Hengrui Medicine, and Huahai Pharmaceutical [1][3] - The trading volume for Rongchang Biologics was notably high, with a turnover rate of 14.96% and a significant drop of 18.36% in stock price [2][3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）全 资子公司翰宇药业（武汉）有限公司（以下简称"翰宇武汉"）醋酸地加瑞克原 料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》（受理 号：CYHS2360753），现将相关情况公告如下： 证券代码：300199 证券简称：翰宇药业 公告编号：2025-033 深圳翰宇药业股份有限公司 关于全资子公司原料药 获得上市申请批准通知书的公告 一、原料药登记信息 1、通用名称：醋酸地加瑞克 2、登记号：Y20230000914 3、包装规格：1g/袋、5g/袋、10g/袋、20g/袋、100g/袋、400g/袋。 4、生产企业：翰宇药业（武汉）有限公司 二、药品的其他情况 地加瑞克是促性腺激素释放激素（GnRH）受体拮抗剂，可逆的与垂体GnRH 受体结合，因而降低促性腺激素和睾丸素释放，可用于治疗晚期前列腺癌患者。 三、对公司的影响 本次醋酸地加瑞克原料药获得上市批准，标志着翰宇武汉取得该原料药国内 市场销售资格，拓宽了原料药产品管线，进一步推 ...

Market Overview - The three major indices experienced a decline, with the ChiNext Index dropping by 1.1% and over 4600 stocks in the market showing negative performance [1][3] - The Shanghai Composite Index fell by 0.86%, the Shenzhen Component Index decreased by 1.01%, and the North China 50 Index also saw a nearly 1% drop, with trading volume exceeding 800 billion, an increase of over 40 billion compared to the previous day [3] Economic Factors - Recent macroeconomic data has shown signs of pressure, leading to hesitance in market recovery expectations [3] - Popular sectors such as AI and weight-loss drugs are experiencing corrections, prompting funds to shift towards defensive sectors [3] - External market instability has also contributed to negative sentiment in the domestic market [3] Sector Performance - Solid-state batteries, PCB, and oil sectors saw gains, with stocks like Nord and Xiangtan Electric achieving limit-up [3] - The solid-state battery sector is gaining attention due to recent technological breakthroughs and a reasonable valuation after previous adjustments in the new energy sector [3] - The oil sector's rise may be linked to geopolitical tensions in the Middle East, particularly the potential for U.S. actions against Iran, leading to short-term oil price volatility [3] Declining Sectors - The nuclear fusion, military, and weight-loss drug sectors faced significant declines, with Changshan Pharmaceutical hitting the limit down and Hanyu Pharmaceutical dropping over 10% [4] - The military sector's adjustment is attributed to a lack of new catalysts, leading to fund withdrawals [4] - The nuclear power sector saw stocks like Hezhan Intelligent and China Nuclear Technology hitting the limit down, possibly due to negative news from specific companies [4] Investment Strategy - In a broad market decline, it is essential to maintain a calm mindset and focus on identifying quality stocks [4] - Long-term investors should prioritize company fundamentals and industry prospects over short-term price fluctuations [4] - The solid-state battery sector is highlighted as a promising long-term investment, while caution is advised in the weight-loss drug sector due to speculative trading [4]

深圳翰宇药业股份有限公司 关于2025年度向金融机构申请综合授信 及担保额度的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司及控股子公司累计对外提供担保总额占最近一期经 审计净资产125.64%、对资产负债率超过70%的单位担保金额占公司最近一期经 审计净资产69.99%；公司及子公司无对合并报表范围外的对外担保事项，也不存 在逾期担保。敬请广大投资者注意风险。 一、授信及担保审议程序 证券代码：300199 证券简称：翰宇药业 公告编号：2025-032 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于2025年2月 28日召开第六届董事会第二次会议、2025年3月17日召开2025年第一次临时股东 大会，审议通过了《关于2025年度申请综合授信及担保额度的议案》，同意公司 及子公司2025年度向金融机构申请综合授信及担保额度总计不超过3.5亿元。其 中：公司为子公司、子公司之间提供综合授信及担保额度5,000万元；子公司为本 公司提供综合授信及担保额度不超过30,000万元。该授信自2025年3 ...